Bailard, Inc. Provention Bio, Inc. Transaction History

Bailard, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$6.71 - $11.04 $277,794 - $457,055	-41,400 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$10.12 - $19.45 $172,040 - $330,650	17,000 Added 69.67%	41,400 $434,000
Q2 2020 Aug 12, 2020	SELL	$7.81 - $17.0 $140,580 - $306,000	-18,000 Reduced 42.45%	24,400 $344,000
Q1 2020 Apr 16, 2020	SELL	$5.42 - $17.75 $42,818 - $140,225	-7,900 Reduced 15.71%	42,400 $390,000
Q4 2019 Jan 31, 2020	SELL	$5.84 - $14.9 $29,200 - $74,500	-5,000 Reduced 9.04%	50,300 $749,000
Q3 2019 Oct 18, 2019	BUY	$6.83 - $13.0 $103,139 - $196,313	15,101 Added 37.57%	55,300 $377,000
Q2 2019 Jul 26, 2019	BUY	$2.3 - $13.79 $92,457 - $554,344	40,199 New	40,199 $486,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.